CLINICAL RESPONSE OF CARBENICILLIN INDANYL SODIUM

Abstract

Carbenicillin indanyl sodium (I-CBPC) was used for the treatment of 480 patients with urinary tract infection at 26 institutions. As for Pseudomonas infection, it would not pertinent to discuss so much on the effective ratio in acute infection because of limited number of cases. However, in 45.5% of complicated chronic infection the causative organism was completely eradicated regardless of the presence or absence of indwelling catheter.
Though the observed therapeutic effectiveness in 44% of cystitis and 46.9% of pyelonephritis seems to be not so remarkable, it is generally accepted that the efficacy rate of around 50% is a sufficient indication of practical usefulness of the drug in case of complicated urinary tract infection due to Pseudomonas.
Furthermore, it is noteworthy that both in bacteriological and clinical aspects I-CBPC has shown similar efficacy rate against Pseudomonas to that against E. coli regarding complicated urinary tract infection.
In general, dosage schedule will be 2 g a day for 7 days for acute and 7-14 days for complicated chronic cases. However, the increase of daily dose to 3 4 g will be recommendable when the causative organism is Pseudomonas in the latter.
Concerning side effects, gastrointestinal disturbances were observed in 11.1 % of the patients and rash in 0.4%. The elevation of either GOT or GPT value was seen in 6 cases. Much attention must be paid to the incidence of anaphylactic shock which occurred in one patient during the therapy.
The application of I-CBPC to the patients with hepatic disorder will not be recommended and caution should be exercised when the patients have renal impairment of moderate to severe degree.